OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung Cancer

July 26th 2024

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC

July 26th 2024

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

Dr Sands on the Evolving Role of ADCs in SCLC Management

July 25th 2024

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

July 25th 2024

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Dr Wirth on the Safety of Selpercatinib in RET Fusion+ Thyroid Cancer

July 25th 2024

Lori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.

Dr Bekaii-Saab on the Ongoing Development of Targeted Therapies in GI Malignancies

July 25th 2024

Tanios Bekaii-Saab, MD, FACP, discusses next-generation sequencing and the development of RAS-targeted therapies in gastrointestinal cancers.

Dr Fürstenau on Safety Data From the GAIA/CLL13 Trial in Untreated CLL

July 25th 2024

Moritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

July 25th 2024

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed Myeloma

July 25th 2024

Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial

Dr Morgans on the Relationship Between PSA Levels and Radiographic Progression in nmCRPC

July 25th 2024

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Posner on the Mechanism of Action of Danivatirsen in HNSCC

July 25th 2024

Marshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.

Dr Saliby on the Correlation Between Intermediate End Points and OS in Metastatic RCC

July 25th 2024

Renee Saliby, MD, MSc discusses the relationship between intermediate end points and overall survival in metastatic renal cell carcinoma.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

July 25th 2024

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

July 25th 2024

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Dr Thompson on Trials Evaluating De-Escalated Treatment in Early-Stage Breast Cancer

July 24th 2024

Alastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing trials evaluating de-escalated treatment in early-stage breast cancer.

Dr Landgren on the Management of Newly Diagnosed Multiple Myeloma Treatment

July 24th 2024

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

Dr Tolaney on the Development of Mutation-Selective PI3K Inhibitors in Breast Cancer

July 24th 2024

Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.

Dr Brufsky on the Unique Design of the Allogeneic SV-BR-1-GM Vaccine in Metastatic Breast Cancer

July 24th 2024

Adam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM.

Dr Watts on the Investigation of INCB057643 in Advanced Myelofibrosis and MPN

July 24th 2024

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer

July 24th 2024

Sara M. Tolaney, MD, MPH, discusses the potential role for biomarkers in guiding treatment decisions in early-stage HER2-positive breast cancer.